Clinical and experimental rheumatology · 2024
The expression of Siglec-10 on naive B cells is involved in the pathology of systemic lupus erythematosus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ju Bomiao, Luo Jing, Hu Nan, Zhang Jing, Zhu Li, Li Qian, Wang Yanhua, Huang Jing, An Qi, Xu Qianyun, Hao Zhiming, Pu Dan, Lv Xiaohong, Li Xin, Huo Yongwei, Zhang Baojun, He Lan
Аннотация
OBJECTIVES: Previous studies have reported the expansion of CD19+Siglec-10+ B cells in systemic lupus erythematosus (SLE) patients. However, the composition of this cell population, phenotype and characteristics are still unknown.
METHODS: We examined this memory B-cell subset's composition and phenotype and determined the SYK and AKT phosphorylation levels by flow cytometry. Additionally, we explored the relationship between Siglec-10 expression on B-cell subsets and clinical manifestations.
RESULTS: Our results indicated elevated levels of Siglec-10 on naive B cells in active SLE patients. Compared with healthy controls (HCs) and inactive SLE patients, the Siglec-10+ B cells in active SLE patients exhibited elevated CD40 and CD21low levels. The levels of Siglec-10 on naive B cells were positively correlated with the proportion of CD21low double negative (DN) B cells and the SLEDAI-2K score.
CONCLUSIONS: The results indicate that the upregulation of Siglec-10+/naive B cells may function as a feedback mechanism to regulate B cell hyperreactivity. Monitoring the proportion of Siglec-10+/naive B cells may contribute to the evaluation of disease progression in SLE.
METHODS: We examined this memory B-cell subset's composition and phenotype and determined the SYK and AKT phosphorylation levels by flow cytometry. Additionally, we explored the relationship between Siglec-10 expression on B-cell subsets and clinical manifestations.
RESULTS: Our results indicated elevated levels of Siglec-10 on naive B cells in active SLE patients. Compared with healthy controls (HCs) and inactive SLE patients, the Siglec-10+ B cells in active SLE patients exhibited elevated CD40 and CD21low levels. The levels of Siglec-10 on naive B cells were positively correlated with the proportion of CD21low double negative (DN) B cells and the SLEDAI-2K score.
CONCLUSIONS: The results indicate that the upregulation of Siglec-10+/naive B cells may function as a feedback mechanism to regulate B cell hyperreactivity. Monitoring the proportion of Siglec-10+/naive B cells may contribute to the evaluation of disease progression in SLE.